KA2507 monohydrochloride
- CAS No.
- 2972712-63-1
- Chemical Name:
- KA2507 monohydrochloride
- Synonyms
- KA2507 monohydrochloride;Benzamide, 4-[(di-2-pyrazinylamino)methyl]-N-hydroxy-, hydrochloride (1:1)
- CBNumber:
- CB613259372
- Molecular Formula:
- C16H14N6O2.ClH
- Molecular Weight:
- 358.78
- MDL Number:
- MOL File:
- 2972712-63-1.mol
- MSDS File:
- SDS
KA2507 monohydrochloride price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| DC Chemicals | DC66334 | KA2507 monohydrochloride >98% | 2972712-63-1 | 100mg | $550 | 2026-05-24 | Buy |
| DC Chemicals | DC66334 | KA2507 monohydrochloride >98% | 2972712-63-1 | 250mg | $850 | 2026-05-24 | Buy |
| DC Chemicals | DC66334 | KA2507 monohydrochloride >98% | 2972712-63-1 | 1g | $1800 | 2026-05-24 | Buy |
KA2507 monohydrochloride Chemical Properties,Uses,Production
Uses
KA2507 hydrochloride is a potent and highly selective inhibitor of HDAC6 (IC50=2.5 nM) with no significant toxicities. KA2507 hydrochloride shows antitumor efficacy and immune modulatory effects[1].
in vivo
KA2507 hydrochloride (100-200 mg/kg; p.o.; daily; for 20 days) inhibits tumor growth in the syngeneic B16-F10 mouse melanoma model[1].
KA2507 hydrochloride also demonstrates antitumor efficacy in CT26 and MC38 colorectal cancer models[1].
Analysis of tumor samples also indicates modulation of biomarkers of antitumor immunity at efficacious dosing, with KA2507 hydrochloride administration resulting in reduced STAT3 activation (as measured by phospho-STAT3, an important suppressor of the antitumor immune response), reduced PD-L1 expression, and increased expression of MHC class I[1].
KA2507 hydrochloride exhibits poor oral bioavailability (mice 15%) and Cmax (mice 300 ng/mL) following oral administration (mice 200 mg/kg)[1].
| Animal Model: | Male C57BL/6 mice, B16-F10 melanoma model[1] |
| Dosage: | 100 mg/kg, 200 mg/kg, |
| Administration: | P.o.; once a day for 20 days |
| Result: | Inhibited tumor growth in the syngeneic B16-F10 mouse melanoma model. |
| Animal Model: | Male C57BL/6 mice, B16-F10 melanoma model[1] |
| Dosage: | 200 mg/kg (Pharmacokinetic Analysis) |
| Administration: | Oral administration |
| Result: | Oral bioavailability (15%), Cmax (300 ng/mL). |
References
[1] Tsimberidou AM, et al. Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. Clin Cancer Res. 2021;27(13):3584-3594. DOI:10.1158/1078-0432.CCR-21-0238
KA2507 monohydrochloride Preparation Products And Raw materials
Raw materials
Preparation Products
KA2507 monohydrochloride Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| Shanghai SuperLan Chemcial Technique Centre | 0-2022843681 15618226720 | chaolaichem@foxmail.com | China | 10000 | 58 |
| Jinan Jiuli Biotechnology Co. , Ltd. | 15865264761 | 486064515@qq.com | China | 4960 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| Zhejiang Huida Biotech Co., Ltd. | 0571-89903022 18679456698 | zilong@hizyme.com | China | 7853 | 58 |
| TargetMol Chemicals Inc. | 13564774135 | marketing@targetmol.com | United States | 19950 | 58 |
View Lastest Price from KA2507 monohydrochloride manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-15 | KA2507 monohydrochloride | 10g | TargetMol Chemicals Inc. |
-
- KA2507 monohydrochloride
- $0.00
- TargetMol Chemicals Inc.
